
First-line selpercatinib prolongs PFS in RET-mutated medullary thyroid carcinoma
Study findings support routine RET-mutation testing for all patients with advanced MTC, but further work is needed to identify predictive markers
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.